The new study was carried out by researchers from the McMaster Stem Cell and Cancer Research Institute at McMaster University in Ontario, Canada.
Mick Bhatia — a professor of biochemistry and biomedical sciences at McMaster University and director of the McMaster Stem Cell and Cancer Research Institute — led the investigation, and the findings have been published in the journal Nature Cell Biology.
As the scientists explain, conventional methods for treating leukaemia focus on targeting leukemic cells, paying little attention to preserving red blood cells.
But the production of healthy blood cells in the bone marrow is crucial for preventing leukaemia patients from having anaemia or fatal infections.
First study author Allison Boyd — a postdoctoral fellow at the McMaster Stem Cell and Cancer Research Institute — says, “Our approach represents a different way of looking at leukaemia and considers the entire bone marrow as an ecosystem, rather than the traditional approach of studying and trying to directly kill the diseased cells themselves.”
“These traditional approaches have not delivered enough new therapeutic options for patients,” she continues. “The standard-of-care for this disease hasn’t changed in several decades.”
The American Cancer Society (ACS) estimates that 21,380 people will be diagnosed with acute myeloid leukaemia (AML) in 2017. Most of these will be adults, as AML tends to target seniors.
Almost half of these patients will die from the disease.
To change these dire survival prospects, Boyd and colleagues collected bone marrow samples from 34 “genetically diverse” patients with AML.
The researchers examined the patients’ blood cell formation process and compared it with that of healthy donors. Boyd and team then examined the behaviour of individual cells both in vitro, or in cell cultures, and in vivo, or in mice that had human cells transplanted into them.
The researchers found that the disease “disrupts the adipocytic niche” in the bone marrow. And more specifically, they found that leukaemia suppresses the bone marrow adipocytes — or the cells that store fat.
This led to dysfunction in the stem cells and progenitor cells, which, in a healthy body, would later go on to form red blood cells. The maturation of red blood cells was therefore stopped.
To combat this, the researchers administered a so-called PPAR-gamma agonist — a drug commonly used to treat type 2 diabetes — to the mice, and they found that it restored the fat cells in the bone marrow.
This “rebirth” of fat cells “rescued healthy hematopoietic maturation while repressing leukemic growth.”
In other words, boosting the fat cells in the bone marrow regenerated the healthy blood cells while killing off the cancerous leukemic ones.
Findings may lead to new therapies
Prof. Bhatia comments on the significance of the findings in the context of traditional anti-leukaemia therapies, saying, “The focus of chemotherapy and existing standard-of-care is on killing cancer cells but instead, we took a completely different approach which changes the environment the cancer cells live in.”
“This not only suppressed the ‘bad’ cancer cells,” he explains, “but also bolstered the ‘good’ healthy cells, allowing them to regenerate in the new drug-induced environment.”
“The fact that we can target one cell type in one tissue using an existing drug makes us excited about the possibilities of testing this in patients,” continues Prof. Bhatia.
“We can envision this becoming a potential new therapeutic approach that can either be added to existing treatments or even replace others in the near future.”
“The fact that this drug activates blood regeneration may provide benefits for those waiting for bone marrow transplants by activating their own healthy cells,” said Prof. Mick Bhatia.
Source: Medical News Today